Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

AOBiome Therapeutics / Equity Capital Markets

AOBiome Therapeutics, a U.S. based biotech company, is planning to raise up to USD 200 million in its listing on the Hong Kong Stock Exchange.
In this insight, we will look at the following topics:
<ul>
<li>Mechanism of the AOB. </li>
<li>The licensing agreement with MBX.</li>
<li>The company's pipeline indications and comparison with current therapies.</li>
<li>The addressable market for the company.</li>
<li>The company's history, investors and management.</li>
</ul>
We will discuss the company's valuation in our next insight.

AOBiome Therapeutics, a U.S. based biotech company, is planning to raise up to USD 200 million in its listing on the Hong Kong Stock Exchange.
In this insight, we will look at the following topics:

Mechanism of the AOB. 
The licensing agreement with MBX.
The company's pipeline indications and comparison with current therapies.
The addressable market for the company.
The company's history, investors and management.

We will discuss the company's valuation in our next insight.

AOBiome Therapeutics IPO: Hope for Natural Therapeutic Treatment

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AOBiome Therapeutics (AOB HK)

AOBiome Therapeutics IPO: Hope for Natural Therapeutic Treatment

AOBiome Therapeutics, a U.S. based biotech company, is planning to raise up to USD 200 million in its listing on the Hong Kong Stock Exchange. In...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)